- Home
- FCAP vs KROS Comparison
FCAP vs KROS Comparison
Compare FCAP & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FCAP | KROS |
|---|---|---|
| Founded | 1891 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.1M | 206.0M |
| IPO Year | 1998 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FCAP | KROS |
|---|---|---|
| Price | $60.80 | $10.19 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.86 |
| AVG Volume (30 Days) | 10.2K | ★ 278.7K |
| Earning Date | 04-24-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.32% | N/A |
| EPS Growth | 36.97 | ★ 146.00 |
| EPS | ★ 1.30 | N/A |
| Revenue | $7,170,000.00 | ★ $243,864,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,751.79 |
| P/E Ratio | $46.12 | ★ N/A |
| Revenue Growth | ★ 1.57 | N/A |
| 52 Week Low | $33.88 | $9.69 |
| 52 Week High | $71.00 | $22.55 |
Technical Indicators
Market Signals| Indicator | FCAP | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 46.90 | 40.60 |
| Support Level | $50.24 | $9.74 |
| Resistance Level | $64.20 | $11.55 |
| Average True Range (ATR) | 2.13 | 0.55 |
| MACD | -0.38 | -0.12 |
| Stochastic Oscillator | 53.48 | 11.23 |
Price Performance
Historical ComparisonAbout FCAP First Capital Inc.
First Capital Inc is an Indiana chartered commercial bank that provides a variety of banking services to individuals and businesses. It provides retail and business banking, residential mortgage lending, real estate finance, and asset-based lending. The bank's primary source of revenue is real estate mortgage loans.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.